Omalizumab Implementation in Practice: Lessons Learned from the OUtMATCH Study

Brian P Vickery,J Andrew Bird,R Sharon Chinthrajah,Stacie M Jones,Corinne A Keet,Edwin H Kim,Donald Y M Leung,Wayne G Shreffler,Scott H Sicherer,Sayantani Sinder,Jonathan Spergel,Robert A Wood

DOI: https://doi.org/10.1016/j.jaip.2024.08.056

2024-09-16

Abstract:In February 2024, omalizumab was approved by the Food and Drug Administration for the treatment of food allergy, based on data from the landmark Phase 3 clinical trial "Omalizumab as Monotherapy and as Adjunct Therapy in Children and Adults (OUtMATCH)." In this Rostrum, OUtMATCH investigators share their perspectives on the trial results, the implications for translation into daily practice, and on remaining gaps in the field. The study met its primary and key secondary endpoints, demonstrating a large effect size in multi-allergen desensitization compared to placebo; yet there were some participants who did not respond, and the percentage of responders tolerating all 3 food allergens was lower than that for single foods. . Clinicians are likely to have many questions about appropriate patient selection, monitoring for treatment responsiveness, and how to manage off-label considerations such as dietary incorporation or co-treatment with oral immunotherapy. Additional research is needed to answer these remaining questions and ensure that the translation of omalizumab in real-world practice leads to high-quality outcomes.